A cross-sectional multicentric study revealed that visfatin in diabetic patients who received drug treatment (such as angiotensin-converting-enzyme inhibitor, calcium channel blockers or statins) couldn’t be used as a biomarker of subclinical atherosclerosis [154]. This evidence concerns the gene NAMPT and atherosclerosis.